NCT06848348Phase 2Active not recruiting

Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

Study sponsor: Dogwood Therapeutics Inc. · DWTX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-12Estimated
Enrollment · participants240Estimated
Source updated2026-09-16Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Primary completion date changed

Before: Jul 2026. After: Dec 2026.

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To explore the efficacy of Halneuron in the treatment of patients with Chemotherapy-Induced Neuropathic Pain Measure: To explore the Safety of Halneuron in the treatment of patients with Chemotherapy-Induced Neuropathic Pain. After: Measure: NRS Pain Measure: Safety Assessments.

Planned enrollment increased by 40 participants

Before: 200 participants (planned). After: 240 participants (planned).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview